HR+/HER2+ breast cancer (BC) is a heterogeneous disease with low pathological complete response (pCR) to standard neoadjuvant treatment. CDK4/6 inhibitors with endocrine and anti-HER2 therapy have shown a potential for chemotherapy omission in this context.
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
Annals of Oncology | | L. Malorni, S. Tyekucheva, A. Gombos, U. Hasler-Strub, C. Zamagni, C. Chakiba-Brugère, M. Colleoni, A. Mueller, A.M. Minisini, D. Taylor, J.P. Salmon, E. Gallerani, A. Cariello, A. Fontana, H. Roschitzki-Voser, R. Kammler, B. Ruepp, S. Loi, G. Viale, M.M. Regan, E. Brain, L. Biganzoli, for the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation) and the TOUCH Trial (IBCSG 55-17) Investigators
Topics: breast-cancer, targeted-therapy, chemotherapy, clinical-trials, research